MedPath

Comparison of Morning or Evening Antihypertensive Drugs on Albuminuria (The MORE trial): A Randomized Control Trial

Phase 1
Completed
Conditions
patients with hypertension presenting albuminuria more than 30 mg/g and taking more than one antihypertensive class more than 3 months
albuminuria, albumin creatinine ratio, evening, hypertension, morning
Registration Number
TCTR20220722005
Lead Sponsor
avamindradhiraj University, Thailand
Brief Summary

Treatment of hypertension with either morning or evening dose regimen did not impact UACR or reduce blood pressure

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
58
Inclusion Criteria

Age 18-80 year
Hypertension for more than 1 year
At least one antihypertensive agent for more than 3 months and at least one antihypertensive agent in Angiotensin-converting enzyme inhibitor (ACEI) and/or Angiotensin receptor blocker (ARB)
Well controlled blood pressure (systolic blood pressure < 150 mmHg, Diastolic blood pressure < 90 mmHg)
albuminuria > 30 mg/g
Renal function (estimated glomerular filtration rate, eGFR > 15 ml/min/1.73 m2)

Exclusion Criteria

End stage kidney disease
Poor control blood pressure
Severe comorbid disease for example congestive heart failure, active cancer
Pregnancy
Inflammatory disease or active infection for example arthritis, pyelonephritis
Study termination criteria
Flare of comorbid disease or active infection (Cancer, acute coronary syndrome or any underlying disease that effect renal function) after included in study

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
rine albumin creatinine ratio 3 months after intervention UACR
Secondary Outcome Measures
NameTimeMethod
Effect to serum creatinine 3 months after intervention serum creatinine ,Effects of blood pressure 3 months after intervention Systolic and diastolic blood pressure
© Copyright 2025. All Rights Reserved by MedPath